You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Pravastatin was not better than usual care in reducing all cause mortality or CHD events

https://doi.org/10.1136/ebm.8.4.106

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Sources of funding: National Heart, Lung, and Blood Institute and Pfizer.

    • For correspondence: Dr J L Probstfield, University of Washington Medical Center, Seattle, WA, USA. jeffp{at}swog.fhcrc.org. Dr B R Davis, University of Texas-Houston Health Science Center, Houston, TX, USA. bdavis{at}sph.uth.tmc.edu

    • Abstract and commentary also appear in ACP Journal Club

    • ↵* See glossary.